Predicting Psychotic Relapse Using Speech-Based Early Detection (NCT06978894)
🩺 Plain-English Summary (8th-Grade Level)
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability. Relapses, characterized by the re-emergence of psychotic symptoms after remission, are a critical factor in the progression of these disorders, increasing risks such as suicide, cognitive impairment, and unemployment. This study aims to develop a novel, speech-based digital model to predict relapses in individuals with psychosis. Building on previous research into language abnormalities in schizophrenia, the study will employ a longitudinal design across Early Psychosis Intervention (EPI) clinics in Ontario and Quebec to advance relapse prediction
Who can join: Review the eligibility criteria below.
Location: Robarts Research Institute — London, Ontario
Age range: 16 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Robarts Research Institute — London, Ontario
- Douglas Mental Health University Institute — Montreal, Quebec
- Vitam — Québec, Quebec
📞 Contact the Study Coordinator
Phone: (514) 761-6131
Email: lena.palaniyappan@mcgill.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psychosis
- Psychosis TMS Study — Charlestown, Massachusetts
- Youth Nominated Support Team — Irvine, California
- Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study — Birmingham, Alabama
- EPI-MINN: Targeting Cognition and Motivation — Duluth, Minnesota
- Probing the Cannabinoid System in Individuals With a Family History of Psychosis — West Haven, Connecticut
- EPI-MINN: Targeting Cognition and Motivation - National — Minneapolis, Minnesota
Explore by condition: All Psychosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.